nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Cataract—Dexamethasone—psoriatic arthritis	0.00623	0.00623	CcSEcCtD
Deferoxamine—Neuropathy—Triamcinolone—psoriatic arthritis	0.00613	0.00613	CcSEcCtD
Deferoxamine—Neuropathy—Methylprednisolone—psoriatic arthritis	0.00612	0.00612	CcSEcCtD
Deferoxamine—Cyanosis—Methotrexate—psoriatic arthritis	0.00609	0.00609	CcSEcCtD
Deferoxamine—Pruritus—Auranofin—psoriatic arthritis	0.00562	0.00562	CcSEcCtD
Deferoxamine—Neuropathy—Dexamethasone—psoriatic arthritis	0.00556	0.00556	CcSEcCtD
Deferoxamine—Neuropathy—Betamethasone—psoriatic arthritis	0.00556	0.00556	CcSEcCtD
Deferoxamine—Visual disturbance—Prednisolone—psoriatic arthritis	0.00544	0.00544	CcSEcCtD
Deferoxamine—Diarrhoea—Auranofin—psoriatic arthritis	0.00544	0.00544	CcSEcCtD
Deferoxamine—Cataract—Prednisone—psoriatic arthritis	0.00542	0.00542	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Prednisolone—psoriatic arthritis	0.00533	0.00533	CcSEcCtD
Deferoxamine—Vomiting—Auranofin—psoriatic arthritis	0.00505	0.00505	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Triamcinolone—psoriatic arthritis	0.0049	0.0049	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methylprednisolone—psoriatic arthritis	0.00489	0.00489	CcSEcCtD
Deferoxamine—Neuropathy—Prednisone—psoriatic arthritis	0.00485	0.00485	CcSEcCtD
Deferoxamine—Bone disorder—Methotrexate—psoriatic arthritis	0.00478	0.00478	CcSEcCtD
Deferoxamine—Nausea—Auranofin—psoriatic arthritis	0.00472	0.00472	CcSEcCtD
Deferoxamine—Visual disturbance—Dexamethasone—psoriatic arthritis	0.00454	0.00454	CcSEcCtD
Deferoxamine—Visual disturbance—Betamethasone—psoriatic arthritis	0.00454	0.00454	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Betamethasone—psoriatic arthritis	0.00444	0.00444	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Dexamethasone—psoriatic arthritis	0.00444	0.00444	CcSEcCtD
Deferoxamine—Asthma—Triamcinolone—psoriatic arthritis	0.0041	0.0041	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisolone—psoriatic arthritis	0.00389	0.00389	CcSEcCtD
Deferoxamine—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.00365	0.00365	CcSEcCtD
Deferoxamine—Infestation—Methylprednisolone—psoriatic arthritis	0.00365	0.00365	CcSEcCtD
Deferoxamine—Bradycardia—Prednisolone—psoriatic arthritis	0.00363	0.00363	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Triamcinolone—psoriatic arthritis	0.00358	0.00358	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Methylprednisolone—psoriatic arthritis	0.00357	0.00357	CcSEcCtD
Deferoxamine—Visual impairment—Prednisolone—psoriatic arthritis	0.00344	0.00344	CcSEcCtD
Deferoxamine—Renal failure acute—Methotrexate—psoriatic arthritis	0.00339	0.00339	CcSEcCtD
Deferoxamine—Bradycardia—Triamcinolone—psoriatic arthritis	0.00334	0.00334	CcSEcCtD
Deferoxamine—Bradycardia—Methylprednisolone—psoriatic arthritis	0.00333	0.00333	CcSEcCtD
Deferoxamine—Visual disturbance—Methotrexate—psoriatic arthritis	0.0033	0.0033	CcSEcCtD
Deferoxamine—Hallucination—Methylprednisolone—psoriatic arthritis	0.00326	0.00326	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.00325	0.00325	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.00325	0.00325	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Methotrexate—psoriatic arthritis	0.00323	0.00323	CcSEcCtD
Deferoxamine—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.00322	0.00322	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisolone—psoriatic arthritis	0.00319	0.00319	CcSEcCtD
Deferoxamine—Visual impairment—Methylprednisolone—psoriatic arthritis	0.00315	0.00315	CcSEcCtD
Deferoxamine—Erythema—Prednisolone—psoriatic arthritis	0.0031	0.0031	CcSEcCtD
Deferoxamine—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00306	0.00306	CcSEcCtD
Deferoxamine—Bradycardia—Dexamethasone—psoriatic arthritis	0.00303	0.00303	CcSEcCtD
Deferoxamine—Bradycardia—Betamethasone—psoriatic arthritis	0.00303	0.00303	CcSEcCtD
Deferoxamine—Angiopathy—Methylprednisolone—psoriatic arthritis	0.00297	0.00297	CcSEcCtD
Deferoxamine—Hallucination—Betamethasone—psoriatic arthritis	0.00296	0.00296	CcSEcCtD
Deferoxamine—Hallucination—Dexamethasone—psoriatic arthritis	0.00296	0.00296	CcSEcCtD
Deferoxamine—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.00296	0.00296	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Deferoxamine—Arrhythmia—Triamcinolone—psoriatic arthritis	0.00293	0.00293	CcSEcCtD
Deferoxamine—Vision blurred—Prednisolone—psoriatic arthritis	0.00293	0.00293	CcSEcCtD
Deferoxamine—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.00292	0.00292	CcSEcCtD
Deferoxamine—Visual impairment—Dexamethasone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Deferoxamine—Visual impairment—Betamethasone—psoriatic arthritis	0.00287	0.00287	CcSEcCtD
Deferoxamine—Erythema—Triamcinolone—psoriatic arthritis	0.00286	0.00286	CcSEcCtD
Deferoxamine—Erythema—Methylprednisolone—psoriatic arthritis	0.00285	0.00285	CcSEcCtD
Deferoxamine—Angioedema—Prednisolone—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.00283	0.00283	CcSEcCtD
Deferoxamine—Eye disorder—Betamethasone—psoriatic arthritis	0.00278	0.00278	CcSEcCtD
Deferoxamine—Eye disorder—Dexamethasone—psoriatic arthritis	0.00278	0.00278	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Deferoxamine—Angiopathy—Betamethasone—psoriatic arthritis	0.0027	0.0027	CcSEcCtD
Deferoxamine—Angiopathy—Dexamethasone—psoriatic arthritis	0.0027	0.0027	CcSEcCtD
Deferoxamine—Convulsion—Prednisolone—psoriatic arthritis	0.00269	0.00269	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Deferoxamine—Arrhythmia—Betamethasone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Deferoxamine—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Deferoxamine—Bradycardia—Prednisone—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Deferoxamine—Angioedema—Triamcinolone—psoriatic arthritis	0.00261	0.00261	CcSEcCtD
Deferoxamine—Angioedema—Methylprednisolone—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Deferoxamine—Erythema—Dexamethasone—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Deferoxamine—Erythema—Betamethasone—psoriatic arthritis	0.00259	0.00259	CcSEcCtD
Deferoxamine—Hallucination—Prednisone—psoriatic arthritis	0.00258	0.00258	CcSEcCtD
Deferoxamine—Connective tissue disorder—Prednisone—psoriatic arthritis	0.00255	0.00255	CcSEcCtD
Deferoxamine—Oedema—Prednisolone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Deferoxamine—Shock—Prednisolone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Deferoxamine—Convulsion—Triamcinolone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Deferoxamine—Tachycardia—Prednisolone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Deferoxamine—Convulsion—Methylprednisolone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Deferoxamine—Myalgia—Triamcinolone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Deferoxamine—Arthralgia—Methylprednisolone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Deferoxamine—Myalgia—Methylprednisolone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Deferoxamine—Eye disorder—Prednisone—psoriatic arthritis	0.00242	0.00242	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Deferoxamine—Angioedema—Betamethasone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Deferoxamine—Angioedema—Dexamethasone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Deferoxamine—Angiopathy—Prednisone—psoriatic arthritis	0.00235	0.00235	CcSEcCtD
Deferoxamine—Immune system disorder—Prednisone—psoriatic arthritis	0.00234	0.00234	CcSEcCtD
Deferoxamine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Oedema—Triamcinolone—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Deferoxamine—Arrhythmia—Prednisone—psoriatic arthritis	0.00232	0.00232	CcSEcCtD
Deferoxamine—Infection—Triamcinolone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Deferoxamine—Infection—Methylprednisolone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Deferoxamine—Shock—Triamcinolone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Deferoxamine—Shock—Methylprednisolone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Deferoxamine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisolone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Deferoxamine—Tachycardia—Triamcinolone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Deferoxamine—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Deferoxamine—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00226	0.00226	CcSEcCtD
Deferoxamine—Erythema—Prednisone—psoriatic arthritis	0.00226	0.00226	CcSEcCtD
Deferoxamine—Convulsion—Betamethasone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Deferoxamine—Convulsion—Dexamethasone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Deferoxamine—Myalgia—Dexamethasone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Deferoxamine—Myalgia—Betamethasone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Deferoxamine—Hypotension—Methylprednisolone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Deferoxamine—Pain—Prednisolone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Deferoxamine—Vision blurred—Prednisone—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Deferoxamine—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Deferoxamine—Oedema—Betamethasone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Deferoxamine—Oedema—Dexamethasone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Deferoxamine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Deferoxamine—Infection—Dexamethasone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Deferoxamine—Infection—Betamethasone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Deferoxamine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Deferoxamine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Deferoxamine—Shock—Dexamethasone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Shock—Betamethasone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Deferoxamine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Deferoxamine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Deferoxamine—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Deferoxamine—Tachycardia—Dexamethasone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Deferoxamine—Tachycardia—Betamethasone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Deferoxamine—Urticaria—Prednisolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Deferoxamine—Pain—Triamcinolone—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Deferoxamine—Hypotension—Dexamethasone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Deferoxamine—Hypotension—Betamethasone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Deferoxamine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Deferoxamine—Paraesthesia—Betamethasone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00187	0.00187	CcSEcCtD
Deferoxamine—Urticaria—Triamcinolone—psoriatic arthritis	0.00185	0.00185	CcSEcCtD
Deferoxamine—Urticaria—Methylprednisolone—psoriatic arthritis	0.00185	0.00185	CcSEcCtD
Deferoxamine—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Deferoxamine—Oedema—Prednisone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Deferoxamine—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Deferoxamine—Infection—Prednisone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Deferoxamine—Shock—Prednisone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Deferoxamine—Pain—Betamethasone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Deferoxamine—Pain—Dexamethasone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Deferoxamine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00172	0.00172	CcSEcCtD
Deferoxamine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Deferoxamine—Urticaria—Dexamethasone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Deferoxamine—Urticaria—Betamethasone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Deferoxamine—Dizziness—Prednisolone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Deferoxamine—Abdominal pain—Betamethasone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Deferoxamine—Body temperature increased—Betamethasone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Deferoxamine—Body temperature increased—Dexamethasone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Deferoxamine—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Deferoxamine—Paraesthesia—Prednisone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Deferoxamine—Pruritus—Triamcinolone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Deferoxamine—Pruritus—Methylprednisolone—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Deferoxamine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Deferoxamine—Headache—Prednisolone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Deferoxamine—Dizziness—Triamcinolone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Deferoxamine—Dizziness—Methylprednisolone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Deferoxamine—Infection—Methotrexate—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Deferoxamine—Nausea—Prednisolone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Deferoxamine—Pruritus—Betamethasone—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Deferoxamine—Pruritus—Dexamethasone—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—psoriatic arthritis	0.00149	0.00149	CcSEcCtD
Deferoxamine—Vomiting—Triamcinolone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Deferoxamine—Vomiting—Methylprednisolone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Deferoxamine—Urticaria—Prednisone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Deferoxamine—Headache—Triamcinolone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Deferoxamine—Headache—Methylprednisolone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Deferoxamine—Diarrhoea—Betamethasone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Deferoxamine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Deferoxamine—Dizziness—Betamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Deferoxamine—Dizziness—Dexamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Deferoxamine—Nausea—Triamcinolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Deferoxamine—Nausea—Methylprednisolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—psoriatic arthritis	0.00137	0.00137	CcSEcCtD
Deferoxamine—Hypersensitivity—Prednisone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Deferoxamine—Vomiting—Dexamethasone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Deferoxamine—Vomiting—Betamethasone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Deferoxamine—Headache—Betamethasone—psoriatic arthritis	0.00132	0.00132	CcSEcCtD
Deferoxamine—Headache—Dexamethasone—psoriatic arthritis	0.00132	0.00132	CcSEcCtD
Deferoxamine—Pain—Methotrexate—psoriatic arthritis	0.00132	0.00132	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Deferoxamine—Nausea—Dexamethasone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Deferoxamine—Nausea—Betamethasone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Deferoxamine—Vomiting—Prednisone—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Deferoxamine—Headache—Prednisone—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Deferoxamine—Nausea—Prednisone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—psoriatic arthritis	0.000978	0.000978	CcSEcCtD
Deferoxamine—Headache—Methotrexate—psoriatic arthritis	0.000964	0.000964	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—psoriatic arthritis	0.000914	0.000914	CcSEcCtD
